CEBPA and acute myeloid leukemia: In this context, we have previously shown that IDH1 mutation primes AML cells to the myeloid differentiation pathway through a 2-HG-mediated activation of the transcription factor CEBPα that sensitizes IDH1 mutant (IDH1MUT) AML cells to differentiation therapy using all-trans retinoic acid (ATRA) [4].